Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

• Status: Recruiting
• Trial end date: 2031-02-22
• Target enrollment: 0
• Participant gender: All

Summary

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Participants must agree to follow the reproductive criteria as outlined in the protocol

• Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

Exclusion Criteria:

• Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

• Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.